Literature DB >> 26758749

Price, value, and the cost of cancer drugs.

Tito Fojo1, Andrew W Lo2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26758749     DOI： 10.1016/S1470-2045(15)00564-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  14 in total

Review 1.  Cancer drug development: The missing links.

Authors:  Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Bethsebie Lalduhsaki Sailo; Nand Kishor Roy; Krishan Kumar Thakur; Kishore Banik; Mehdi Shakibaei; Subash C Gupta; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2019-04-08

2.  Reply to A. Wong et al.

Authors:  Victoria L Chiou; Mauricio Burotto
Journal:  J Clin Oncol       Date:  2016-02-29       Impact factor: 44.544

3.  How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?

Authors:  R Andrew Harkins; Christopher R Flowers
Journal:  Leuk Lymphoma       Date:  2020-11-04

4.  An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries.

Authors:  Jean-Jacques Body; Francesca Gatta; Erwin De Cock; Sunning Tao; Persefoni Kritikou; Pauline Wimberger; Jeroen Mebis; Marc Peeters; Paolo Pedrazzoli; Augusto Caraceni; Vincenzo Adamo; Guy Hechmati
Journal:  Support Care Cancer       Date:  2017-04-21       Impact factor: 3.603

Review 5.  Cost-effectiveness of Colorectal Cancer Screening and Treatment Methods: Mapping of Systematic Reviews.

Authors:  Hossein Mashhadi Abdolahi; Ali Sarabi Asiabar; Saber Azami-Aghdash; Fatemeh Pournaghi-Azar; Aziz Rezapour
Journal:  Asia Pac J Oncol Nurs       Date:  2018 Jan-Mar

6.  Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future.

Authors:  Kim Pauwels; Isabelle Huys; Sabine Vogler; Minne Casteels; Steven Simoens
Journal:  Front Pharmacol       Date:  2017-04-04       Impact factor: 5.810

Review 7.  Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends.

Authors:  Muhammad Farhan Sohail; Mubashar Rehman; Hafiz Shoaib Sarwar; Sara Naveed; Omer Salman; Nadeem Irfan Bukhari; Irshad Hussain; Thomas J Webster; Gul Shahnaz
Journal:  Int J Nanomedicine       Date:  2018-06-08

8.  Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan.

Authors:  Etsuko Satoh; Yasutsuna Sasaki; Ryotaro Ohkuma; Takehiro Takahashi; Yutaro Kubota; Hiroo Ishida; Kazuyuki Hamada; Yuji Kiuchi; Takuya Tsunoda
Journal:  Cancer Sci       Date:  2018-11-27       Impact factor: 6.716

9.  Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Wânia Cristina da Silva; Vânia Eloisa de Araujo; Ellias Magalhães E Abreu Lima; Jessica Barreto Ribeiro Dos Santos; Michael Ruberson Ribeiro da Silva; Paulo Henrique Ribeiro Fernandes Almeida; Francisco de Assis Acurcio; Brian Godman; Amanj Kurdi; Mariângela Leal Cherchiglia; Eli Iola Gurgel Andrade
Journal:  BioDrugs       Date:  2018-12       Impact factor: 5.807

10.  Funds Reimbursement of High-Cost Drugs in Gastrointestinal Oncology: An Italian Real Practice 1 Year Experience at the National Cancer Institute of Naples.

Authors:  Monica Capozzi; Chiara De Divitiis; Alessandro Ottaiano; Tramontano Teresa; Maurizio Capuozzo; Piera Maiolino; Gerardo Botti; Salvatore Tafuto; Antonio Avallone
Journal:  Front Public Health       Date:  2018-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.